23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Clinical Trials Using The ExAblate(R) Non-Invasive Prostate System

Links shared publicly online about this topic.

  • 148
    total visits

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Clinical Trials Using The ExAblate(R) Non-Invasive Prostate System

medicalnewstoday.com

InSightec Ltd., the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate® system for treating uterine fibroids, announced toda

View full resource at medicalnewstoday.com

Tags: Cancer, Prostate Cancer, Prostate, Imaging Tests, Ultrasound, Clinical Trial, Men's Health

  • Share

Most Recently Shared on July 14, 2011 at 9:38 am By:

Drugs_Devices Drugs and Devices OW

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Clinical Trials Using T... http://bit.ly/oxnrif #MedDevice

10 months ago...

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Clinical Trials Using The ExAblate(R) Non-Invasive Prostate System

medicalnewstoday.com — “InSightec Ltd., the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate® system for treating uterine fibroids, announced todaView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on July 14, 2011 at 8:05 am By:

mnt_drugapprov MNT Drug Approvals Health News

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated In Clinical Trials Using The ExAblate(R) No... http://mnt.to/3Yfq

10 months ago...

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated in Clinical Trials Using the ExAblate(R) Non-Invasive Prostate Cancer System - Health News - redOrbit

redorbit.com — “TIRAT CARMEL, Israel, July 13, 2011 /PRNewswire/ -- Initial Results are Encouraging, Spurring Hope for a Treatment Option With a Lower Rate of Complications InSightec Ltd., the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that 23 patients with organ confined low risk prostate cancer have already been treated with its ExAblate(R) system in clinical trials, showing proView full resource at redorbit.com

  • View Related
  • Share

Most Recently Shared on July 13, 2011 at 5:48 pm By:

Urology_Wisdom Urology & Nephrology OW Health

23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated in Clinical Trials Using the ExAblate... http://bit.ly/qwJIsc

10 months ago...

Advertisement